

ABSTRACT

A cancer gene therapeutic drug of the present disclosure comprises a combination of: a virus for immunological treatment to be administered for inducing a CTL reaction within a living body to the administration of the carrier cell; and a carrier cell to be infected with an oncolytic virus before the administration so as to make the oncolytic virus act on a tumor cell within the living body. For example, A549 cell can be used as the carrier cell, a non-proliferative adenovirus inactivated by UV irradiation can be used as the virus for immunological treatment, and a proliferative adenovirus having a tumor-specific promoter can be used as the oncolytic virus.